Derivatives of 1, 3, 4 - Oxadiazoles, Pharmaceutical compositions containing same and use in preparation of a Medicament for the treatment of diseases mediated by the inhibition of the activity of the DGAT1.

摘要

This paper introduces the dgat-1 formulation (1) inhibitors for drugs and their acceptable salts, as well as the drug composition, preparation process and treatment process, such as 0, 1, 2 or 3 obesity; R is independently selected between fluorine, chlorine, bromine and trifluoromethyl, Methoxy, dimethoxy, trifluoromethy and Z are carboxy, or carbohydrates or their microbial or biological isomers, or hydroxy, hydroxyethyl, or in which Rb and RC are independently selected from H and C1-4 tar,C1-4 alkyl group which may be optionally substituted with carboxy or with a mimic or bioisoster thereof. Claim 6: The (1r, 4r) -4- (4- (5- (3,4-difluorphenylamino) -1,3,4-oxadiazol-2-carboxamido) -3-fluorophenyl) cyclohexanecarboxylic acid compound characterized by a standard X-ray powder diffraction with specific peaks at approximately 2-theta = 16.2s and 27.6 °.